Hydrogen chloride

Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
星期二, 五月 21, 2024
Patient, Hydrogen chloride, Tonix Pharmaceuticals, Polypharmacy, Medicare, Food, NDA, Prevalence, GTM, Diagnosis, FDA, Inflation, Database, Research, Physician, Tablet, Fatigue, Fibromyalgia, Female, Pharmaceutical industry

Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.

Key Points: 
  • Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.
  • Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy.
  • “The primary research and analysis conducted by EVERSANA provides valuable insights and informs the vision for the commercialization of Tonmya,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • Key findings from claims data analyses2:
    ~2.7 million adults in the U.S. currently diagnosed and treated for fibromyalgia.

Lion One Drills 4.8 m of 30.48 g/t Gold in Near-Mine Expansion at Tuvatu

Retrieved on: 
星期三, 五月 8, 2024
Diamond, ICP-AES, Element, QAQC, SSW, News, MAIG, NQ, ICP-OES, Qualified person (European Union), National instrument, HQ, Hydrogen chloride, ALS, Pathfinder, Orientation, AA, PQ, SKL, HF, Mining

The Murau drilling included in this release targeted the down-dip extension of the Murau system.

Key Points: 
  • The Murau drilling included in this release targeted the down-dip extension of the Murau system.
  • A total of 34 Murau drillholes are included in this release, including 18 holes drilled from underground and 16 drilled from surface.
  • They typically have limited lateral extent, approximately 50 m to 100 m, but with very high bonanza grades (>30 g/t gold).
  • The drillholes reported here are the first modern drillholes designed to target the SKL lodes and represent near-mine expansion of the Tuvatu resource.

CENTURY LITHIUM ANNOUNCES POSITIVE FEASIBILITY STUDY FOR THE CLAYTON VALLEY LITHIUM PROJECT, NEVADA

Retrieved on: 
星期一, 四月 29, 2024
Lithium, Benchmark Mineral Intelligence, Project, Sale, DLE, Filtration, H2SO4, Risk, Pilot plant, Sodium chloride, GRE, Project management, Mineral, Area studies, Lithium carbonate, Transport, QP, Mineral Resources Limited, AACE, FOB, Hydrochloric acid, Patent, MMSA, Feasibility study, Sodium hydroxide, Commerce, Hydrogen chloride, Century, Mining, CIM, Electrolysis, Recycling, G&A, Saltern

The QP for the estimate is Ms. Terre Lane, MMSA, an employee of GRE and independent of Century.

Key Points: 
  • The QP for the estimate is Ms. Terre Lane, MMSA, an employee of GRE and independent of Century.
  • Metallurgical testing through 2020 focused on using sulfuric acid (H2SO4) to extract lithium from the clay.
  • A lithium recovery of 78% is used in the Feasibility Study, based on the data collected in over two years of operations at the Pilot Pant.
  • Contributors to the estimates are GRE (mining), Wood (process plant and infrastructure), ThyssenKrupp Nucera (chlor-alkali plant) and Century Lithium (property information and owners' costs).

Lion One Drills 448.98 g/t, 202.34 g/t, and 108.5 g/t Gold at Tuvatu, Provides Operations Update

Retrieved on: 
星期四, 四月 25, 2024
Diamond, ICP-AES, QAQC, SSW, News, MAIG, NQ, 1101, Gold, ICP-OES, Qualified person (European Union), National instrument, HQ, Hydrogen chloride, ALS, CIL, CAT, Pathfinder, Mining, AA, PQ, Element, HF

Drilling below the 1101 level is targeting URW1 down-dip extension, drilling above the 1101 level is grade control drilling.

Key Points: 
  • Drilling below the 1101 level is targeting URW1 down-dip extension, drilling above the 1101 level is grade control drilling.
  • The Murau lode system dips moderately to the SSW and is open down dip and at depth.
  • The Murau lode system will be the second area to enter production in Zone 2 after the URW1 lode system.
  • An access drive has been completed on the 1161 level and will provide access for the longhole drills and larger loaders.

Globex Acquires Gold Exploration Target in Arizona, USA

Retrieved on: 
星期四, 三月 21, 2024
Dorado, B-68, Element, Gneiss, Perchloric acid, Geo, Silver, Vein, B-29, ICP-OES, Hydrogen chloride, AAL, Salt, Gold, GMX, Toronto Stock Exchange, HF, B-34, B-19, HNO3, Glass, H3BO3, Linearity, B-47, Mining

The project area is at the northernmost margin of the historic Gold Basin Mining District.

Key Points: 
  • The project area is at the northernmost margin of the historic Gold Basin Mining District.
  • In the area covered by Globex’s Salt Spring property Globex has identified 14 small mine workings and at least 15 prospects.
  • Globex already carried out preliminary fieldwork including geological mapping and collected a total of 70 rock samples.
  • Obtained gold values above 10 g/t were re-analyzed via fire assay of a 30 g subsample and gravimetric determination.

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
星期三, 三月 20, 2024
Fibromyalgia, Partnership, Patient, Tablet, Hydrogen chloride, NDA, Tonix Pharmaceuticals, Fatigue, Food, CMOS, Pharmaceutical industry

CHATHAM, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has selected two contract manufacturing organizations (CMOs), one of which is Almac Pharma Services, a member of the privately owned Almac Group, as dual supply sources for the potential launch and commercialization of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S.

Key Points: 
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Statistically significant and clinically meaningful results (p=0.001 or better) were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies, and no new safety signals were observed.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia.

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Retrieved on: 
星期二, 三月 19, 2024
Quality control, Fibromyalgia, Tablet, Hydrogen chloride, Acquisition, Commercial, Tonix Pharmaceuticals, Therapy, Marketing, FDA, Sumatriptan, Food, Pharmaceutical industry

CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024. Since the acquisition of Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals has been putting in place the personnel, systems and contracts required to support a commercial organization. Both products are indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary
    Commercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya™ for the management of fibromyalgia, assuming FDA approval
    CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024.
  • Since the acquisition of Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals has been putting in place the personnel, systems and contracts required to support a commercial organization.
  • Both products are indicated for the treatment of acute migraine with or without aura in adults.
  • “Tonix will become a fully integrated biopharmaceutical company with a mission of developing and marketing innovative, high-value therapeutics,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
星期三, 三月 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.

Hydrochloric Acid Market Size to Grow by USD 978.77 million, 5.72% YOY market growth in 2023-2024, Technavio

Retrieved on: 
星期四, 三月 14, 2024
Carbon, Resin, Chlorine, PVC, Hydrochloric acid, BASF, Growth, Occidental Petroleum, Olin Corporation, Steel, Tessenderlo Group, COVID-19, Hydrogen chloride, Alkyl polyglycoside, APG, Food, Synthetic, AGC, Fructose, Merck Group, HFCS, Mining, Hazardous waste, Chemistry, Drink, Vinyl chloride, Optimism, Ground substance, USD, SGL Carbon, PCC, Palladium

The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.

Key Points: 
  • The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global hydrochloric acid market.
  • Expansion of hydrochloric acid facilities, like SGL Carbon's unit delivery to Travancore-Cochin Chemicals Ltd., drives market growth, enabling companies to enhance their market presence and offer a wider product range, boosting the global hydrochloric acid market.
  • Substitutes like emerald-safe acid, phosphoric acid, sodium bisulfate, and trisodium phosphate pose challenges to hydrochloric acid market growth.

Lion One Provides Update on Tuvatu Operations in Fiji

Retrieved on: 
星期一, 三月 4, 2024
Diamond, LIMS, ALS, PQ, Mining, NQ, News, HQ, MAIG, Qualified person (European Union), Hydrogen chloride, Gold, Laboratory information management system, AA, ASX, Element, National instrument, Pathfinder, QAQC, HF, Zone 2, ICP-AES, ICP-OES, CIL

North Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) (ASX: LLO) ("Lion One" or the "Company") is pleased to provide an update on ongoing operations at the company's 100% owned Tuvatu Alkaline Gold Project in Fiji.

Key Points: 
  • North Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) (ASX: LLO) ("Lion One" or the "Company") is pleased to provide an update on ongoing operations at the company's 100% owned Tuvatu Alkaline Gold Project in Fiji.
  • The Tuvatu project is currently in the pilot plant stage of operations.
  • The focus of mining operations to date has been on the development of underground access.
  • Diamond drill core samples are logged and split by Lion One personnel on site and delivered to the Lion One Laboratory for preparation and analysis.